Catalyst, Endo sign definitive agreement for vigabatrin tablets

Catalyst Pharmaceuticals (CPRX) announced that it has signed a Definitive Agreement with Endo International’s (ENDP) subsidiary, Endo Ventures, for the further development and commercialization of generic Sabril tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to the agreement, Catalyst will receive an up-front payment, milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization. Vigabatrin comes in two dosage forms – a powder sachet and a tablet. Par Pharmaceutical brought the first generic version of the powder sachet to market but at this time there is no approved generic version of the tablets.
https://thefly.com/landingPageNews.php?id=2838747